The US Food and Drug Administration (USFDA) has issued Form 483 with five observations to an active pharmaceutical ingredients (API) plant of Dr Reddy's Laboratories Limited.
In a Bombay Stock Exchange (BSE) filing on Friday, the company said plant-3 at Bollaram on the city outskirts has recieved these observations upon completion of an inspection.
"These observations are related to procedures and facility maintenance. We will address them

)